2024年

１．Yamamoto T, Hayashida T, Masugi Y, Oshikawa K, Hayakawa N, Itoh M, Nishime C, Suzuki M, Nagayama A, Kawai Y, Hishiki T, Matsuura T, Naito Y, Kubo A, Yamamoto A, Yoshioka Y, Kurahori T, Nagasaka M, Takizawa M, Takano N, Kawakami K, Sakamoto M, Wakui M, Yamamoto T, Kitagawa Y, Kabe Y, Horisawa K, Suzuki A, Matsumoto M, Suematsu M, PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer. Cancer Res. 2024 Apr 1;84(7):1065-1083, 2024.04, IF=11.2 

 

２．Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K, Yajima S, Yashiro M, Yokoi K, Cho H, Ehira T, Nakahara K, Yasuda H, Isobe K, Hayashida T, Hatakeyama S, Akakura K, Aoki D, Nomura H, Tada Y, Yoshimatsu Y, Miyachi H, Takebayashi C, Hanamura I, Takahashi H, Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2, Int J Clin Oncol. 2024 May;29(5):512-534, 2024.05, IF=2.4   

​

３．Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022, Int J Clin Oncol, 2024 May;29(5):551-558, 2024.05, IF=2.5 

​

４．Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H, Nakamura T,  Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer, Oncologist, Oncologist. 2024 Jun 3;29(6):e741-e749. 2024.06, IF=4.8 

​

５．Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022, Int J Clin Oncol, 2024 Jun;29(6):681-688, 2024.06, IF=2.5 

​

６．Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn J, Parsons H, Wander SA, Attaya V, Lormil B, Shellock M, Nagayama A, Bossuyt V, Isakoff SJ, Tolaney SM, Ellisen LW, Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer, Clin Cancer Res. 2024 Jul 15;30(14):2917-2924, 2024.07, IF=10.0 

​

７．Nozawa K, Ozaki Y, Yoshinami T, Yokoe T, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022, Int J Clin Oncol, 2024 Aug;29(8):1074-1080, 2024.08, IF=2.5 

​

８．Hirai I, Tanese K, Nakamura Y, Fukuda K, Ouchi T, Hayashida T, Kameyama K, Abe T, Amagai M, Funakoshi T, Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC), Oncologist. 2024 Sep 6;29(9):e1201-e1208, 2024.09, IF=4.8 

​

９．Tomita H, Ienaga N, Kajita H, Hayashida T, Sugimoto M, An analysis on the effect of body tissues and surgical tools on workflow recognition in first person surgical videos, Int J Comput Assist Radiol Surg, 2024 Nov;19(11), 2024.11, IF=2.3 

​

​

2023年

１．Nagayama A, Kitagawa Y. Managing Seroma Formation Post Breast Surgery through Somatostatin Analogs. JMA J, 14;6(3):282-283. 2023.07 IF=1.5

 

２．Wang Y, Gao B, Zhang L, Wang X, Zhu X, Yang H, Zhang F, Zhu X, Zhou B, Yao S, Nagayama A, Lee S, Ouyang J, Koh SB, Eisenhauer EL, Zarrella D, Lu K, Rueda BR, Zou L, Su XA, Yeku O, Ellisen LW, Wang XS, Lan L, Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair, Nat Commun, 2024 Feb 21;15(1):1568, IF=14.7 

​

​

2022年

１．T Hayashida, E Odani, M Kikuchi, A Nagayama, T Seki, M Takahashi, N Futatsugi,A Matsumoto, T Murata, R Watanuki, T Yokoe, A Nakashoji, H Maeda, T Onishi, SAsaga, T Hojo, HJinno, K Sotome, A Matsui, A Suto, S Imoto, Y Kitagawa,Establishment of a deep-learning system to diagnose BI-RADS4a or higher usingbreast ultrasound for clinical application,Cancer Science 2022Jul;113(10) 3528-3534,IF=5.72.Takeshi Sato,Mikako Inokuchi,Satsuki Nakano,Yu Iwabuchi,Tetsu Hayashida,Tomohiro Ishii,Tomonobu Hasegawa,Fluorodeoxyglucose-positron emissiontomography as a potential alternative tool forfunctional diagnosis of glycogenstorage disease type I,Radiol Case Rep 2022 Oct18(1)91-93,IF=1.03.

 

２．Kubo A, Masugi Y, Hase T, Nagashima K, Kawai Y, Takizawa M, Hishiki T, ShiotaM, WakuiM, Kitagawa Y, Kabe Y, Sakamoto M, Yachie A, Hayashida T, SuematsuM. Polysulfide Serves as a Hallmark of Desmoplastic Reaction to DifferentiallyDiagnose Ductal Carcinoma In Situ and Invasive Breast Cancer by SERS Imaging.Antioxidants(Basel), 2023 Jan;12(2):240,IF=64

​

３．Shimomura A,Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A,Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, HiguchiT, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A.Clinicopathological features, genetic alterations, and BRCA1 promoter methylationin Japanese male patients with breast cancer. Breast Cancer Res Treat,2023.Feb197(3):593-602,IF=3

 

過去の一覧